다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

PRME

Prime Medicine (PRME)

Prime Medicine Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:PRME

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/22	05:06	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:PRME	Prime Medicine Inc
2024/05/22	05:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PRME	Prime Medicine Inc
2024/05/13	21:00	GlobeNewswire Inc.	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	NASDAQ:PRME	Prime Medicine Inc
2024/05/10	21:22	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PRME	Prime Medicine Inc
2024/05/10	21:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PRME	Prime Medicine Inc
2024/05/10	21:00	GlobeNewswire Inc.	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates	NASDAQ:PRME	Prime Medicine Inc
2024/05/08	21:00	GlobeNewswire Inc.	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)	NASDAQ:PRME	Prime Medicine Inc
2024/05/01	21:00	GlobeNewswire Inc.	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference	NASDAQ:PRME	Prime Medicine Inc
2024/04/29	20:00	GlobeNewswire Inc.	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)	NASDAQ:PRME	Prime Medicine Inc
2024/04/23	21:00	GlobeNewswire Inc.	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings	NASDAQ:PRME	Prime Medicine Inc
2024/03/01	22:09	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:PRME	Prime Medicine Inc
2024/03/01	22:04	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:PRME	Prime Medicine Inc
2024/03/01	22:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PRME	Prime Medicine Inc
2024/03/01	22:00	GlobeNewswire Inc.	Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates	NASDAQ:PRME	Prime Medicine Inc
2024/02/28	22:00	GlobeNewswire Inc.	Prime Medicine to Participate in Upcoming Investor Conferences	NASDAQ:PRME	Prime Medicine Inc
2024/02/24	07:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PRME	Prime Medicine Inc
2024/02/24	07:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PRME	Prime Medicine Inc
2024/02/23	11:31	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:PRME	Prime Medicine Inc
2024/02/21	07:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PRME	Prime Medicine Inc
2024/02/21	06:01	GlobeNewswire Inc.	Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares	NASDAQ:PRME	Prime Medicine Inc
2024/02/16	20:23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PRME	Prime Medicine Inc
2024/02/16	20:17	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PRME	Prime Medicine Inc
2024/02/15	13:50	GlobeNewswire Inc.	Prime Medicine Announces Pricing of Upsized Public Offering	NASDAQ:PRME	Prime Medicine Inc
2024/02/15	11:57	Edgar (US Regulatory)	Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses	NASDAQ:PRME	Prime Medicine Inc
2024/02/15	07:27	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PRME	Prime Medicine Inc
2024/02/15	06:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PRME	Prime Medicine Inc
2024/02/15	06:05	GlobeNewswire Inc.	Prime Medicine Announces Proposed Public Offering of Common Stock	NASDAQ:PRME	Prime Medicine Inc
2024/01/25	22:00	GlobeNewswire Inc.	Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis	NASDAQ:PRME	Prime Medicine Inc
2024/01/08	22:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PRME	Prime Medicine Inc
2024/01/06	07:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PRME	Prime Medicine Inc

검색 관련기사 보기:NASDAQ:PRME

1 2 3 4 다음 >>

Vontobel Financial Produ...

Sabrient Small Cap Growt...

Mirion Technologies

Vontobel Financial Produ...

Societe Generale Effekten

Sao Domingos Fundo Inves...

US Dollar vs MGA

삼일씨엔에스

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관